Palvella Therapeutics Inc. Ordinary Shares PVLA 深 滬
交易中 11-04 10:19:56 美东时间
74.54
-2.300
-2.99%
華盛通- 最 高76.25
- 今 開75.315
- 成交量 1.45万股
- 最 低 74.54
- 昨 收 76.84
- 總市值 8.24亿
- 52周最高 83.00
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 11.17
- 委 比 -43.66%
- 總股本 1105.97万
- 歷史最高 83.00
- 量 比 0.92
- 振 幅 2.23%
- 歷史最低 11.17
- 每 手 1
- 風險率 18.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palvella Receives Second-Year FDA Grant to Fund Phase 3 Trial of QTORIN for Rare Skin Disease
(NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases
10-13 19:35
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Truist Securities Maintains Buy on Palvella Therapeutics, Raises Price Target to $80
Truist Securities analyst Danielle Brill maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $56 to $80.
10-03 00:24
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Palvella Therapeutics Expands QTORIN Rapamycin Development Into Rare Angiokeratomas With No FDA-Approved Therapies For Over 50,000 US Patients
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than
09-24 18:03
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
Palvella Therapeutics plans to expand its QTORIN™ rapamycin gel development to address clinically significant angiokeratomas, a rare, chronic skin condition without FDA-approved treatments. The company aims to initiate a Phase 2 trial in late 2026. QTORIN™ is also being tested for other rare skin diseases, with results expected in early 2026. Palvella held a webcast conference call on September 24, 2025, to discuss this expansion.
09-24 10:00
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
Palvella Therapeutics announced the publication of a systematic review in *Lymphatic Research and Biology* outlining rapamycin's potential in treating cutaneous venous malformations (VMs). The review, analyzing 26 studies with 98 patients, highlights rapamycin's efficacy in VMs despite limited FDA-approved options. Palvella's QTORIN™ 3.9% rapamycin gel, currently in Phase 2 testing, targets the mTOR pathway linked to VM proliferation. Researchers...
09-17 11:30
